What are you looking for?

FDA Recall: Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication – FDA Requests Withdrawal of Weight-Loss Drug

As of January 2020 the FDA issued the following safety communication: The FDA has requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the...
READ MORE

Jury hits J&J with $8 billion verdict for male breast growth linked to Risperdal

$8 Billion. That is an angry jury sending a message. Congratulations to our friends Jason Itkin and Tom Kline at Arnold & Itkin and Kline...
READ MORE

Diclofenac NSAID Painkiller Linked To An Increase In Heart Attacks

A recent major study done by the British Medical Journal shows that Diclofenac can increase the risk of heart attack and stroke by 50%. Diclofenac...
READ MORE

Torrent Pharmaceuticals Limited Issue Voluntary Recall of Valsartan / Amlodipine / HCTZ Tablets

The Food and Drug Administration has reported that Torrent Pharmaceuticals Limited is voluntarily recalling 14 lots of Valsartan / Amlodipine / HCTZ Tablets. This recall...
READ MORE

The FDA Recalls Thyroid Medications Due To Possible Contamination

The FDA has recalled hypothyroid medications manufactured by Westminster Pharmaceuticals after their Chinese manufacturing plant did not meet the FDA’s standards. The initial inspection took...
READ MORE

Truvada Lawsuit

When new medicines came to market in the 1990s and 2000s, they drastically changed the way people with HIV and AIDS were treated—often making the...
READ MORE

Zofran and Entresto Recall Packages

Beware of kids getting into Zofran (Ondansetron), Risperidone, onepezil ODT, Naratriptan, or Entresto (sacubitril / valsartan) drug packages. Two drug companies, Sandoz and Novartis, recall...
READ MORE
N/A FDA Recall: Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication – FDA Requests Withdrawal of Weight-Loss Drug FDA Recall: Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication – FDA Requests Withdrawal of Weight-Loss Drug
N/a
KBA Attorneys

As of January 2020 the FDA issued the following safety communication:

The FDA has requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer. The drug manufacturer, Eisai, has submitted a request to voluntarily withdraw the drug.

When FDA approved lorcaserin in 2012, FDA required the drug manufacturer to conduct a  clinical trial to evaluate the risk of cardiovascular problems. A range of cancer types was reported, with several different types of cancers occurring more frequently in the lorcaserin group, including pancreatic, colorectal, and lung.

If you or a loved one has contracted one of the above types of cancers and was taking Belviq or Belviq XR, please contact us immediately for a free evaluation of your claim.


2020 Progress Court
Suite 100-147

Raleigh NC 27608